The problem
Seeing a doctor in the Middle East ran on phone calls, personal recommendations, and walk-ins: patients had no trusted way to compare doctors or confirm appointments, while clinics bled revenue to no-shows and managed schedules on paper.
How it works
Vezeeta’s platform lets patients search, review, and book doctors and medical services across more than 50 cities in Egypt, Saudi Arabia, Jordan, and Lebanon. On the provider side, hospitals and clinics plug in Vezeeta’s practice-management solutions to handle bookings, schedules, and ongoing patient engagement — digitising both ends of the appointment.
Pain points
Opaque doctor availability and unverified quality; phone-booking friction and long waits; clinics losing slots to no-shows; and patients with no single digital record of their provider relationships.
Business model
A B2B2C healthcare platform: free patient search-and-booking builds demand and data, while monetisation sits on the provider side through booking services and practice-management software sold to hospitals and clinics.
Challenges
Marketplace bookings without deep transaction capture make profitability slow in a fragmented healthcare market; investor marks reported in 2026 imply a valuation far below earlier peaks, signalling limited investor appetite; and Egypt’s currency volatility and macro instability squeeze a Cairo-headquartered cost base serving regional markets.
Funding
- Raised: $40M Series D (Feb 2020) led by Gulf Capital, with existing investor STV participating — LAFFAZ.
- Earlier: $12M Series C (2018) led by Saudi-based STV, followed by an IFC investment — IFC’s first direct investment in an Egyptian technology company (MENAbytes, Dec 2018).
- Investor base also includes Vostok New Ventures.
Latest — February 2026
Launch Base Africa’s analysis of VNV Global’s December 2025 portfolio valuations showed Vezeeta gaining 66% during 2025 (adding $1.05M to VNV’s holding) — a recovery from a very low base, with VNV’s 9% stake still marked about 72% below its original $9.4M cost, implying roughly a $29M company valuation on a stale 4.5x revenue multiple from a September 2022 transaction. The piece framed Vezeeta as a slowly recovering asset facing fragmented competition and an unproven path to profitability.